William Damsky MD
Dermatopathology
Assistant Professor of Dermatology and Pathology
Join to View Full Profile
428 Columbus AveNew Haven, CT 06519
Phone+1 203-503-3000
Fax+1 203-785-7637
Dr. Damsky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterResidency, Internal Medicine, 2013 - 2014
University of Vermont College of MedicineClass of 2013
Certifications & Licensure
FL State Medical License 2022 - Present
CT State Medical License 2017 - 2026
American Board of Dermatology Dermatology- American Board of Dermatology Dermatopathology
Clinical Trials
- Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare Start of enrollment: 2019 Apr 11
- Janus Kinase Inhibition in Sarcoidosis Start of enrollment: 2023 Jun 01
Roles: Principal Investigator, Contact
- Janus Kinase Inhibition in Granuloma Annulare Start of enrollment: 2023 Oct 27
Roles: Sponsor-Investigator, Principal Investigator, Contact
Publications & Presentations
PubMed
- Cutaneous lupus features specialized stromal niches and altered retroelement expression.Jeff R Gehlhausen, Yong Kong, Emily Baker, Sarika Ramachandran, Fotios Koumpouras
The Journal of Investigative Dermatology. 2025-05-21 - Jak1 Inhibition Is Sufficient for Treatment of Granuloma Annulare.Muhammad H Junejo, Erica Hwang, Okeroghene Rufin, Bridget E Shields, Misha Rosenbach
The Journal of Investigative Dermatology. 2025-05-16 - Grover disease shows type 2 immune activation and improves with dupilumab.Michael J Murphy, Muhammad H Junejo, Okeroghene Rufin, Jeffrey M Cohen, Caroline A Nelson
The British Journal of Dermatology. 2025-04-28
Press Mentions
Novel LDTs Advance Dermatological DiagnosticsFebruary 14th, 2025- TNF or JAK: Which Target Is Key to Success in Tough-to-Treat Skin Disease?November 11th, 2021
- Dramatic Responses in Cutaneous Sarcoidosis with JAK InhibitorNovember 7th, 2021
- Join now to see all
Grant Support
- Delineation of the immunobiology of sarcoidosis and characterization of the effects of Janus kinase inhibitionYALE UNIVERSITY2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
